Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
collection:"CTG"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?lookfor=%22PARP+inhibitor%22&type=Subject&filter%5B%5D=collection%3ACTG
/vufind/Search/Results?lookfor=%22PARP+inhibitor%22&type=Subject&filter%5B%5D=collection%3ACTG
Search /vufind/Search2/Results?lookfor=%22PARP+inhibitor%22&type=Subject&filter%5B%5D=collection%3ACTG
PubPharm (13)
1
Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients : Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: the First Real-word Evidence From China
enthalten in:
ClinicalTrials.gov
| 2021
Wird geladen...
2
Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd : Combination Talazoparib - Carboplatin for Recurrent High-grade Glioma With DNA Damage Repair Deficiency (DDRd)
enthalten in:
ClinicalTrials.gov
| 2021
Wird geladen...
3
A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients : A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients who have: Cohort 1 – platinum resistant disease and are PARP inhibitor naïve; Cohort 2 – had at least 1 prior line of therapy which must include at least 1 line of platinum-based chemotherapy followed by PARP inhibitor maintenance
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
4
A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients : A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients who have: Cohort 1 – platinum resistant disease and are PARP inhibitor naïve; Cohort 2 – had at least 1 prior line of therapy which must include at least 1 line of platinum-based chemotherapy followed by PARP inhibitor maintenance
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
5
Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor : A Single-arm Phase II Study of Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor
enthalten in:
ClinicalTrials.gov
| 2021
Wird geladen...
6
The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer : A Real-world Study of Clinical Markers for PARP Inhibitors in Epithelial Ovarian Cancer
enthalten in:
ClinicalTrials.gov
| 2021
Wird geladen...
7
A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients : A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients who have: Cohort 1 – platinum resistant disease and are PARP inhibitor naïve; Cohort 2 – had at least 2 prior lines of therapy which must include at least 1 line of platinum-based chemotherapy followed by PARP inhibitor maintenance
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
8
A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients : A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients who have: Cohort 1 – platinum resistant disease and are PARP inhibitor naïve; Cohort 2 – had at least 2 prior lines of therapy which must include at least 1 line of platinum-based chemotherapy followed by PARP inhibitor maintenance
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
9
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer : A Prospective, Single-arm, Single-center, Exploratory Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
enthalten in:
ClinicalTrials.gov
| 2020
Wird geladen...
10
Phase Ib/II study to evaluate the efficacy and tolerability of PM01183 in combination with olaparib in patients with advanced solid tumors : Phase Ib/II study to evaluate the efficacy and tolerability of PM01183 in combination with olaparib in patients with advanced solid tumors - POLA
enthalten in:
WHO International Clinical Trials Registry Platform
| 2019
Wird geladen...
1
2
Nächster »
[2]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Filter aufheben
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Medienart
13
Aufsätze
13
E-Artikel
13
E-Ressourcen
Zeitschriftentitel
8
WHO International Clinical Trials Registry Plat...
5
ClinicalTrials.gov
Thema
13
610
11
Study Type: Interventional
9
Phase: Phase 2
6
Recruitment Status: Authorised-recruitment may ...
4
Carcinoma, Ovarian Epithelial
4
Ovarian Neoplasms
4
Recruitment Status: Recruiting
3
Recruitment Status: Not yet recruiting
2
Hypersensitivity
2
Medical Condition: Advanced or metastatic solid...
2
Medical Condition: Advanced ovarian cancer pati...
2
Medical Condition: Advanced ovarian cancer pati...
2
Medical Condition: Clinical trial of the combin...
2
Phase: Phase 1
2
Study Type: Observational
1
Adnexal Diseases
1
Carcinoma
1
Genital Neoplasms, Female
1
Glioblastoma
1
Glioma
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
9
2020-
4
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
13
Englisch
Haven't found what you're looking for?
Wird geladen...